Acute Ischemic StrokeCAT-AISNCT07819526
Acute Ischemic Stroke in Patients With Active Cancer
An observational study of Acute Ischemic Stroke and Active Cancer, run by Osaka University at 1 site in Japan.
Trial summary
The goal of this multicenter prospective observational study, conducted at 24 hospitals in Japan, is to learn about recurrent ischemic stroke in people with active cancer who develop acute ischemic stroke. One of the main objectives is to evaluate how often ischemic stroke recurs during follow-up. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Acute Ischemic Stroke, Active Cancer
- How many people
- 500 participants
- Where
- 1 siteJapan
- Study dates
- 1 Mar 2026to 31 Mar 2032
- How long will I take part?
- 3 Months
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study population will consist of participants with acute ischemic stroke and active cancer who receive medical care at participating hospitals in Japan. Eligible participants will be enrolled prospectively during the study enrollment period.
Who may be able to join
- Acute ischemic stroke diagnosed within 7 days after symptom onset or the time last known well.
- Active cancer at the time of the index stroke, as defined below.
Who cannot join
- The patient or a legally acceptable representative indicates that the patient does not wish to participate.
- The investigator considers enrolment inappropriate.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Japan1 site, 1 recruiting
- Recruiting
The Univeristy of Osaka
Suita, Osaka, 565-0871
Yasufumi Gon, MD, PhD, +81-6-6879-5111, gon@neurol.med.osaka-u.ac.jp
About this study
Official title: Clinical Characteristics and Stroke Recurrence in Patients With Acute Ischemic Stroke and Active Cancer: The CAT-AIS Multicenter Prospective Observational Study
The goal of this multicenter prospective observational study, conducted at 24 hospitals in Japan, is to learn about recurrent ischemic stroke in people with active cancer who develop acute ischemic stroke. One of the main objectives is to evaluate how often ischemic stroke recurs during follow-up.
The main questions this study aims to answer are:
Read more
- How often does ischemic stroke recur within 3 months after the initial stroke?
- Which clinical factors may be associated with recurrent ischemic stroke?
- What other clinical outcomes occur during follow-up?
Participants will receive medical care determined by their treating physicians. Researchers will collect information about participants' cancer, stroke characteristics, test results, treatments, recurrent ischemic stroke, and other clinical outcomes. Researchers will also explore whether clinical factors are associated with recurrent ischemic stroke and other outcomes. This study will not assign participants to a specific treatment.
- Conditions
- Acute Ischemic Stroke, Active Cancer
- Keywords
- Cancer-associated ischemic stroke, Recurrent ischemic stroke, Cancer, Antithrombotic therapy
- Medical subject headings
- Ischemic Stroke, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Participants with acute ischemic stroke and active cancer | Participants with active cancer who develop acute ischemic stroke and are enrolled prospectively at participating hospitals. Clinical information, treatments, recurrent ischemic stroke, and other outcomes will be collected during follow-up. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Recurrent Ischemic Stroke Within 3 Months
The percentage of participants who experience recurrent ischemic stroke during follow-up. Recurrent ischemic stroke will be determined according to the criteria prespecified in the study protocol.
Measured: From enrollment through 3 months of follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2026
- Study start1 Mar 2026
- Primary completion30 Jun 2027 (estimated)
- Study completion31 Mar 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Ischemic StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Osaka University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07819526
- Sponsor's protocol ID
- 25379
- Acronym
- CAT-AIS
- Status last verified
- Sep 2026
- First submitted
- 9 Sep 2026
- Last updated
- 21 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared because no data-sharing plan has been established for this study. Study findings will be reported only in aggregate form.